USA |NASDAQ |USD |ADR
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Oct 30, 2021 (est) | Sep 30, 2021 | - | $-0.17 | $-0.16 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Oct 30, 2021 (est) | Sep 30, 2021 | - | $0.00 | $0.00 |
Enlivex Therapeutics's next estimated earnings date (based on same quarter last year's date) is Oct 30, 2021 for the fiscal quarter ending Sep 30, 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $-0.28 | $-0.28 | $-0.28 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $-0.86 | $-0.86 | $-0.86 |
| Dec 2022 | 1 | $-1.54 | $-1.54 | $-1.54 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.28 | $-0.28 | $-0.31 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.86 | $-0.86 | $-1.01 |
| Dec 2022 | 0 / 0 | $-1.54 | $-1.54 | $-1.60 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $0.00 | $0.00 | $0.00 |
| Dec 2022 | 1 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 6, 2021 | Jun 2021 | $-0.26 | $-0.17 | 34.62% |
| Apr 30, 2021 | Mar 2021 | $-0.25 | $-0.43 | -72.00% |
| Feb 26, 2021 | Dec 2020 | $-0.25 | $-0.43 | -72.00% |
| Oct 30, 2020 | Sep 2020 | $-0.18 | $-0.16 | 11.11% |
| Aug 14, 2020 | Jun 2020 | $-0.24 | $-0.23 | 4.17% |
| May 18, 2020 | Mar 2020 | $-0.24 | $-0.07 | 70.83% |
| Feb 21, 2020 | Dec 2019 | $-0.25 | $-0.28 | -12.00% |
| Nov 14, 2019 | Sep 2019 | - | $-0.23 | - |
| Jul 26, 2019 | Jun 2019 | - | $-0.14 | - |
| Apr 30, 2019 | Mar 2019 | - | $-0.69 | - |
| Feb 23, 2018 | Dec 2017 | - | $-1.36 | - |
| Nov 2, 2017 | Sep 2017 | - | $-2.56 | - |
| Aug 4, 2017 | Jun 2017 | - | $-3.97 | - |
| May 26, 2017 | Mar 2017 | $-11.60 | $-6.40 | 44.83% |
| Feb 24, 2017 | Dec 2016 | $-10.80 | $-7.60 | 29.63% |
| Nov 29, 2016 | Sep 2016 | $-8.80 | $-11.20 | -27.27% |
| Aug 25, 2016 | Jun 2016 | $-0.27 | $-1.10 | -307.41% |
| May 25, 2016 | Mar 2016 | $-0.28 | $-1.60 | -471.43% |
| Feb 23, 2016 | Dec 2015 | $-0.25 | $-0.34 | -36.00% |
| Nov 17, 2015 | Sep 2015 | $-0.29 | $-0.25 | 13.79% |
| Aug 21, 2015 | Jun 2015 | $-0.28 | $-0.26 | 7.14% |
| May 19, 2015 | Mar 2015 | $-0.24 | $-0.23 | 4.17% |
| Feb 17, 2015 | Dec 2014 | $-0.15 | $-0.22 | -46.67% |
| Nov 21, 2014 | Sep 2014 | $-0.08 | $-0.16 | -100.00% |
| Aug 29, 2014 | Jun 2014 | - | $-4.04 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 26, 2021 | Dec 2020 | $-0.72 | $-0.89 | - |
| Feb 21, 2020 | Dec 2019 | - | $-1.35 | - |
| Feb 23, 2018 | Dec 2017 | $0.00 | $-14.30 | - |
| Feb 24, 2017 | Dec 2016 | - | $-21.50 | - |
| Feb 23, 2016 | Dec 2015 | - | $-1.08 | - |
| Feb 17, 2015 | Dec 2014 | - | $-4.42 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 6, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| Apr 30, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Feb 26, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Oct 30, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 14, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 18, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Feb 21, 2020 | Dec 2019 | - | $0.00 | - |
| Nov 14, 2019 | Sep 2019 | - | $0.00 | - |
| Jul 26, 2019 | Jun 2019 | - | $0.00 | - |
| Apr 30, 2019 | Mar 2019 | - | $0.00 | - |
| Feb 23, 2018 | Dec 2017 | - | $0.00 | - |
| Nov 2, 2017 | Sep 2017 | $0.00 | $0.00 | - |
| Aug 4, 2017 | Jun 2017 | $0.00 | - | - |
| May 26, 2017 | Mar 2017 | - | - | - |
| Feb 24, 2017 | Dec 2016 | - | - | - |
| Nov 29, 2016 | Sep 2016 | - | - | - |
| Aug 25, 2016 | Jun 2016 | - | - | - |
| May 25, 2016 | Mar 2016 | - | - | - |
| Feb 23, 2016 | Dec 2015 | - | - | - |
| Nov 17, 2015 | Sep 2015 | - | - | - |
| Aug 21, 2015 | Jun 2015 | - | - | - |
| May 19, 2015 | Mar 2015 | - | - | - |
| Feb 17, 2015 | Dec 2014 | - | - | - |
| Nov 21, 2014 | Sep 2014 | - | - | - |
| Aug 29, 2014 | Jun 2014 | - | - | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 26, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Feb 21, 2020 | Dec 2019 | - | $0.00 | - |
| Feb 23, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Feb 24, 2017 | Dec 2016 | - | $0.00 | - |
| Feb 23, 2016 | Dec 2015 | - | - | - |
| Feb 17, 2015 | Dec 2014 | - | - | - |
ENLV's next estimated earnings date (based on same quarter last year's report date) is Oct 30, 2021 for the fiscal quarter ending Sep 30, 2021.
Enlivex Therapeutics's previous earnings date was Aug 6, 2021 for its fiscal quarter ended Jun 30, 2021.
ENLV's earnings per share (EPS) was $-0.17, beating the consensus analysts forecast of $-0.26 by 34.62%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -60.47%, and higher than the same period a year before (Jun 2020) by -26.09%.
Revenues were $0.00.
The company reported a net income of $-3.11M.Free cash flow for the quarter was $-4.71M , compared to $-2.51M last quarter and $-3.80M a year before.
ENLV ended the quarter with $210.00K in total debt, an increase of 2.44% compared to the previous quarter, and a decrease of -41.50% compared to the same quarter a year before.
Enlivex Therapeutics's previous annual earnings date was Feb 26, 2021 for its fiscal year ended Dec 31, 2020.
ENLV's earnings per share (EPS) was $-0.89, missing the consensus analysts forecast of $-0.72 by 23.61% , and higher than the previous year's EPS (Dec 2019) by -33.97%.
Revenues were $0.00.
The company reported a net income of $-11.82M.
Enlivex Therapeutics reported a free cash flow of $-12.03M for its fiscal year, compared to $-7.23M a year ago.
The company ended the fiscal year with $203.00K in total debt, an increase of 65.04% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
